Micron Technology, Inc. (MU) Earnings

Micron Technology, Inc. is expected to report next earnings on June 24, 2026 (in NaN days), with a consensus EPS estimate of $19.62. MU has beaten EPS estimates in 11 of its last 12 reported quarters (average surprise +19.7% over the last four).

Next earnings
Jun 24, 2026in NaN days
EPS est $19.62 · Revenue est $34.3B
Track record
Beat EPS in 11 of 12 quarters
Avg surprise +19.7% (last 4 quarters)
Earnings history
Report dateEPS estEPS actualSurpriseRevenueRev. surprise
Mar 18, 2026$9.19$12.20+32.8%$23.9B+19.5%
Dec 17, 2025$3.96$4.78+20.7%$13.6B+5.7%
Sep 23, 2025$2.86$3.03+5.9%$11.3B+0.9%
Jun 25, 2025$1.60$1.91+19.4%$9.3B+4.9%
Mar 20, 2025$1.43$1.56+9.1%$8.1B+2.0%
Dec 18, 2024$1.75$1.79+2.3%$8.7B-0.1%
Sep 25, 2024$1.12$1.18+5.4%$7.8B+1.3%
Mar 20, 2024$-0.25$0.42+266.2%$5.8B+8.9%
Dec 20, 2023$-0.99$-0.95+4.0%$4.7B-1.7%
Dec 21, 2022$-0.01$-0.04-194.6%$4.1B-1.2%
Jun 30, 2022$2.43$2.59+6.6%$8.6B-0.0%
Dec 20, 2021$2.11$2.16+2.4%$7.7B+2.2%

Source: company filings + earnings calendar. For informational purposes only — not investment advice.

Earnings call summary

Q2 FY2026 · March 18, 2026

AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.

Management highlights

Strategic pillars: Driving commercial adoption - 2025 was a record year of installed base expansion with 340 new accounts added, closing the year with 1,465 U.S. accounts. Advancing plaque innovation pipeline - Drove strong early momentum in plaque account additions, closed 2025 with 489 accounts, launched next generation plaque algorithm, pulled forward PCI Navigator launch to April 2026, and announced AI-driven efficiency initiative Partflow Autonomous Processing. Extending clinical leadership - Accelerate evidence generation through prospective trials and peer-reviewed publications, launched Navigate PCI registry, presented real world data from Mass General Brigham plaque registry, plan to report one-year outcomes from DECIDE registry, and plan to expand into high-risk asymptomatic population with three randomized controlled trials.

Guidance

Initiating full year 2026 revenue guidance in the range of $218 million to $222 million. Initiating non-GAAP gross margin guidance of 80% to 81%. Increasing midterm non-GAAP gross margin target from 80% to 85%. PLAC revenue for 2026 is expected to be approximately $15 million to $17 million, weighted towards the back half.

Segment performance

Total fourth quarter revenue was $49.1 million, representing more than a 40% year-over-year growth. Global cases grew nearly 53% year-over-year. Achieved a record non-GAAP gross margin of nearly 80%. Initiating full year 2026 revenue guidance in the range of $218 million to $222 million, representing a year-over-year growth of approximately 24 to 26 percent. Full-year 2026 PLAC revenue is expected to reach approximately $15 million to $17 million. Initiating full year 2026 non-GAAP gross margin guidance of 80 to 81%, and increasing midterm non-GAAP gross margin target to 85%.

Analyst Q&A

  • Q: Robbie Marcus with JPM asked about 2026 guidance and plaque,

    A: John Farquhar responded on confidence in the business, drivers of FFRCT growth, plaque progress.

  • Q: William Plovnik with Canaccord Genuity asked about product innovations and PCI Navigator,

    A: John Farquhar talked about product innovations like next gen plaque algorithm, PCI Navigator launch, and Vikram Virghese discussed FFRCT case numbers and guidance phasing.

  • Q: Matthew O'Brien with Piper Sandler asked about plaque revenue per case and gross margin,

    A: John Farquhar and Vikram Virghese spoke about plaque pricing, gross margin drivers.

  • Q: Larry Bigelson with Wells Fargo asked about plaque utilization and clinical data,

    A: John Farquhar discussed plaque utilization and clinical education efforts.

  • Q: Rick Wise with Stifel asked about CCTA adoption and competition,

    A: John Farquhar talked about CCTA adoption progress and competitive positioning focusing on data and product quality